Oral PrimeC for ALS significantly reduced toxic TDP-43 protein levels in a Phase 2b trial. PrimeC also slowed functional decline and extended survival by about 15 months. The treatment was well ...

Clene, Inc. reports significant survival benefits from CNM-Au8® treatment for ALS in recent survival analyses from the HEALEY trial. Clene, Inc. announced promising results from a post hoc analysis of ...

After news that Eric Dane has been diagnosed with amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s Disease, ...

The blood biomarkers serum albumin and creatinine appear to be associated with survival in patients with amyotrophic lateral sclerosis (ALS) and may help define prognosis in patients after they are ...

SALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) -- Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the ...

Living in a disadvantaged community may decrease the length of time a person can survive with amyotrophic lateral sclerosis, or ALS, by over 30%, a Michigan Medicine-led study suggests. ALS is a ...

Researchers from University of Arizona present a new therapeutic target to shield nerve cells from the damage of ALS.

With the help of artificial intelligence, a coalition of Bay Area institutions identified 18 FDA-approved drugs that could improve the lives of those suffering from amyotrophic lateral sclerosis, ...

Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...

AB SCIENCE IS INVITED TO PRESENT AT THE 2026 ENCALS ANNUAL MEETING THE SURVIVAL DATA FROM MASITINIB CLINICAL PROGRAM IN AMYOTROPHIC LATERAL SCLEROSIS Masitinib treatment has been linked to a 5-year ...